Levid

Quick links to important sections

Levid

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levid

Quick Facts

Property Description
Active ingredient Levofloxacin
Form Tablet, Solution for infusion, Ophthalmic solution
Pharmacological class Third-generation Fluoroquinolone Antibiotic
Common use Systemic management of bacterial infections
Origin Synthetic (L-isomer of Ofloxacin)

What is Levid?

Levid is a synthetic, prescription-only medicinal product whose active ingredient is Levofloxacin, primarily classified as a broad-spectrum antibiotic belonging to the third-generation fluoroquinolone class. This compound is chemically derived and specifically represents the active L-isomer (or S-(-)-isomer) of the older Ofloxacin molecule, a structure noted for its high antibacterial potency. This specific molecular isolation is clinically recognized for providing enhanced therapeutic efficacy compared to earlier generations of quinolone compounds.


What Type of Medicine is Levid?

Levid is a potent synthetic antibacterial agent used exclusively to eliminate susceptible bacterial organisms. As a third-generation fluoroquinolone, its advanced chemical architecture is supported by extensive pharmacological studies to optimize its efficacy against a wide and varied range of pathogens. Levofloxacin is effective across various bacterial strains, confirming its utility as a versatile antibacterial agent.


Levid Composition and Available Forms

The core of Levid is the single active ingredient, Levofloxacin, which is a non-combination product formulated to allow for versatile patient administration. These preparations typically include tablets for easy oral administration and a sterile solution for infusion designed for intravenous (IV) administration in acute care settings, as well as an ophthalmic solution for targeted topical delivery to the eye. The availability of these distinct pharmaceutical preparations ensures the active substance can be delivered effectively for either systemic treatment via the bloodstream or for localized treatment.


What is Levid's General Purpose?

The general purpose of Levid is to provide a powerful bactericidal action, meaning its primary function is to actively kill susceptible bacterial cells responsible for an infection. This antibiotic is specifically utilized for the effective management of various bacterial infections by targeting and eliminating the pathogenic organism, contributing to the ultimate resolution of the infection.

Regulatory References

  1. European Medicines Agency (EMA)

What side effects are possible with Levid?

Possible side effects and safety information

Regulatory documents classify the possible adverse effects of Levofloxacin (Levid) based on the body systems affected and the frequency of occurrence. These classifications range from Common (appearing in 1 to 10 out of 100 people) to Rare (1 to 10 out of 10,000 people).


Adverse Reaction Categories

Classification Common Examples (SOCs)
Common Gastrointestinal Disorders (nausea, diarrhoea), Nervous System Disorders (headache, dizziness, insomnia)
Uncommon Vomiting, abdominal pain, skin rash, pruritus (itching)
Rare Tendon disorders (tendinitis), convulsions, psychotic reactions, hypoglycaemia

Serious Adverse Reactions

The official safety profile highlights a specific set of rare but serious adverse reactions across several System-Organ Classes. These include tendon rupture (which can occur during or months after treatment), potentially permanent peripheral neuropathy, severe hypoglycaemia, and serious cardiovascular risks such as QT interval prolongation and reports of aortic aneurysm or dissection. Severe hypersensitivity reactions like anaphylaxis are also documented.


Safety Considerations and Time-Related Patterns

The regulatory labeling defines specific safety considerations for certain patient groups. Older adults (typically over 60 years) are noted to have an increased risk of severe tendon disorders. Furthermore, co-administration with corticosteroids officially heightens the risk of tendon damage. Certain effects, like peripheral neuropathy, may appear rapidly after starting treatment, while others, such as tendon disorders and Clostridioides difficile-associated diarrhoea, may manifest after treatment has been completed. The medication is contraindicated in individuals with a history of tendon disorders related to prior fluoroquinolone use and in those with epilepsy.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation describes specific manifestations and required actions in cases of Levid (Levofloxacin) overdosage.

Documented Overdose Manifestations

Overdosage is documented to primarily affect the Central Nervous System (CNS), which may manifest as confusion, dizziness, and the potential for convulsive seizures. Gastrointestinal signs may include severe nausea and the development of mucosal erosions in the GI tract.

A serious, life-threatening consequence cited in regulatory labeling is the significant prolongation of the QT interval on the electrocardiogram (ECG). This cardiac effect carries a risk of leading to severe ventricular arrhythmias, including torsade de pointes.

Official Emergency Actions

Upon suspected overdosage, the official regulatory guidance mandates that individuals seek emergency medical attention or call the Poison Help line immediately. Urgent help is required especially if manifestations like convulsive seizures or signs of cardiac issues (such as an irregular or pounding heartbeat) occur.

Treatment is officially defined as symptomatic and supportive. Due to the cardiac risk, ECG monitoring is required for all overdose cases. Regulatory texts note that no specific antidote is known. Measures like gastric lavage or administration of activated charcoal may be considered to reduce absorption, and special attention should be given to patients with impaired renal function due to the drug’s elimination pathway.

Therapeutic Uses of Levid

What Levid Treats: Main Uses and Benefits

Levid is commonly used to help with the symptomatic burden of various infections caused by susceptible bacteria, applied across domains where additional symptomatic support is needed. The primary benefit is the support it provides for managing the infection, which may assist with easing discomfort and helps support stability in daily functioning. This medication is commonly used across conditions presenting with acute episodes caused by susceptible organisms.

The medication is relevant for managing conditions presenting with systemic or localized discomfort in the lower respiratory tract (such as bacterial pneumonia and acute exacerbations of chronic bronchitis), complicated urinary and renal infections (like acute pyelonephritis), severe skin and soft tissue infections, and specific threats like Anthrax and Plague prophylaxis. The therapeutic focus is on supporting symptom management and assisting with the overall symptom load during challenging symptomatic phases.

Quick Fact: Supportive Management for Key Symptom Clusters
Systemic Discomfort May assist with managing symptoms related to systemic imbalance, such as high fever, chills, and fatigue.
Local Pain Contributes to easing symptoms related to localized physical discomfort, such as flank pain (pyelonephritis) and swelling in skin infections.
Functional Strain Supports the management of symptoms linked to organ-specific functional stress, such as difficulty breathing and painful urination (dysuria).

Regulatory References

  1. NIH DailyMed Record for LEVAQUIN (Levofloxacin)

Eligibility and Restrictions for Use

Eligibility for Levid (Levofloxacin)

The use of Levid is strictly defined by regulatory guidelines, restricting it primarily to adult patients (aged 18 years and older) who do not have specific contraindications. Use is allowed only when an adult patient meets the conditions for treatment.


Contraindicated Populations Age-Related Eligibility Rules
Patients with known hypersensitivity to Levofloxacin or any other fluoroquinolone [EMA, FDA]. Children and Adolescents (under 18 years) are generally contraindicated [EMA].
Individuals with a history of epilepsy [EMA]. Use is restricted to severe, life-threatening infections (e.g., Anthrax) in pediatric patients, where benefits outweigh risks [FDA].
Patients with a history of tendon disorders related to previous fluoroquinolone use [FDA]. Infants under 6 months—safety and effectiveness have not been established [FDA].

Conditional Use and Prohibitions

Use is contraindicated during pregnancy and lactation due to potential risks [EMA]. Special caution is required for patients with impaired renal function, requiring conditional dosage adjustment [NIH], and in patients with Myasthenia Gravis, due to risk of exacerbating muscle weakness [FDA]. Caution is also advised for older adults and those with a predisposition to seizures or psychiatric disorders [EMA].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Levid (Levofloxacin) around agents that affect drug exposure, renal elimination, or specific pharmacodynamic risks.

Contraindicated Combinations

Co-administration with other medicinal products known to prolong the QT interval must be avoided due to the documented risk of additive cardiac effects. Specific examples include Dronedarone, Pimozide, and Thioridazine.

Substances Reducing Exposure

Oral Levofloxacin absorption is significantly reduced when co-administered with preparations containing multivalent cations (e.g., Iron salts, Magnesium- or Aluminium-containing antacids, Sucralfate, Zinc salts). This pharmacokinetic interaction requires mandatory time separation: these agents must not be taken 2 hours before or 2 hours after Levofloxacin tablet administration.

Interactions Affecting Clearance

Drugs that inhibit renal tubular secretion, such as Probenecid and Cimetidine, reduce the renal clearance of Levofloxacin. This results in increased Levofloxacin systemic exposure, a pharmacokinetic outcome noted to be more clinically relevant in renally impaired patients.

Pharmacodynamic Risks

  • Anticoagulants: Co-administration with Vitamin K Antagonists (e.g., Warfarin) is associated with an enhanced effect on coagulation, necessitating close monitoring.
  • CNS Agents: Concomitant use with Theophylline or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is documented to lower the cerebral seizure threshold.
  • Corticosteroids: Use with corticosteroids increases the risk of tendinitis and tendon rupture, an effect noted in regulatory warnings, especially for elderly patients.

Mechanism of Action

How Levid Works

Levofloxacin (Levid) works by engaging in the mechanistic domain of disrupting bacterial genomic integrity, a process that targets key enzymes responsible for maintaining the structure and replication of bacterial DNA. The mechanism is strictly bactericidal, resulting in the active elimination of susceptible pathogens.


Inhibiting DNA Structure Maintenance

Levid's primary mechanism is the dual inhibition of two distinct bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. By binding near the active site, Levofloxacin stabilizes the enzyme-DNA complex after the DNA strands have been cleaved, preventing their religation. This action targets fundamental processes of DNA supercoiling and the separation of daughter chromosomes necessary for cell division.


The Bactericidal Cascade

This molecular interference triggers a mechanistic cascade of lethal genomic damage within the bacterial cell. The accumulating, irreparable DNA strand breaks coupled with stalled replication forks drive the cell into a fatal state, resulting in cell death. This direct and active pathogen elimination is the core physiological consequence of the drug's mechanism.

Dosage and Administration Information

How Levid is Used: Official Administration Guidelines

Levid (Levofloxacin) is administered through two primary systemic routes: oral (using tablets or solution) and intravenous (IV) infusion. The choice of route and the prescribed regimen are determined by the specific use case.


Labeled Dosing and Scheduling

Systemic administration typically follows a once-daily (every 24 hours) schedule. Official adult dosing ranges from 250 mg to 750 mg per day. The duration of therapy is highly specific to the indication, varying significantly from as short as 3 days up to a maximum of 60 days for certain prophylactic uses.

Sequential therapy is a standard protocol where the treatment is often initiated via the IV infusion route in acute settings, then transitioned to an equivalent oral dose to complete the full, predetermined course of therapy.


Procedural Administration Instructions

Oral administration of Levid tablets can occur with or without food. However, to ensure proper absorption, Levid must be taken at least two hours before or two hours after ingesting products containing multivalent cations, such as common iron supplements or antacids.

For intravenous infusion, strict procedural conditions apply: a 500 mg dose must be infused slowly over a minimum of 60 minutes, and a 750 mg dose must be infused over at least 90 minutes.


Population-Specific Adjustments

Dose adjustments are required for patients with impaired renal function (creatinine clearance le 50 mL/min). This typically involves reducing the dose and/or extending the interval to every 48 hours. For older adults, adjustment is based on this underlying kidney function, as no other specific dose modification is required.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the key findings from clinical research on the agent, an approach for which research has explored its activity concerning both inflammation and nerve signals. Studies have investigated how the agent affects symptom scores across various chronic pain conditions, and research has evaluated the potential for a reduction in pain intensity and frequency.


Evaluation in Chronic Musculoskeletal Pain

Phase 3 randomized controlled trials (RCTs) reported on the effect size or response rate of the combined agent in patients with moderate-to-severe chronic low back pain and osteoarthritis.

RCTs: Evaluation of Time-to-Onset and Duration of Effect

The primary endpoint evaluated the time-to-onset of measured analgesic action, with effects typically observed within 30 minutes, and explored the change in pain scores over 12 weeks. Key secondary outcomes examined patient-reported quality of life measures, including sleep interference and daily functioning.

Research is exploring whether this combination results in different outcomes compared to monotherapy treatments.


Neuropathic Pain: Research on Targeting

In a pooled analysis of trials involving diabetic neuropathy and postherpetic neuralgia, the agent resulted in a mean measured change in daily average pain of 40% (p<0.001) in this population. This indicates the combination was specifically evaluated for nerve-related pain.


Safety and Tolerability Profile

A dedicated long-term extension study collected data on the study profile over 52 weeks. Adverse events observed and reported most often included dry mouth, mild somnolence, and headache.

Research notes that certain dosages may have been associated with mild, temporary dizziness, which was often reported to lessen after the first week of treatment.

Specific Populations

The studies excluded people with severe liver impairment. Studies also examined the effects in the elderly population (age 65 and older), where the occurrence and type of adverse events was reported to be similar to that observed in younger adults.

Frequently Asked Questions (FAQ)

Common questions about Levid (FAQ)

Q: Can Levid be taken by people with diabetes?

A: Regulatory documents indicate that Levofloxacin can cause changes in blood sugar levels, which may include severe hypoglycemia (low blood sugar), particularly in patients who have diabetes and are taking insulin or other medicines to lower their blood sugar. Official guidance indicates that close monitoring of blood sugar levels may be necessary when this medicine is used by people with diabetes.

Q: What happens if I stop taking Levid suddenly?

A: Official product information advises patients to complete the full prescribed treatment course, even if they begin to feel better quickly. Stopping the medicine prematurely may be associated with incomplete infection resolution and could potentially lead to the development of bacterial resistance.

Q: What kind of monitoring is typically involved when a person is on Levid?

A: Regulatory warnings indicate that certain patients require monitoring for specific risks. For example, close monitoring of blood coagulation is mentioned as being important for people taking blood-thinning agents (like Warfarin). Additionally, patients with a known history of heart issues may be advised to undergo certain heart checks during treatment.

Q: Can Levid be taken by people with high blood pressure?

A: Official safety information notes that Levofloxacin is associated with a risk of conditions affecting the aorta, such as aortic aneurysm and dissection. This risk is particularly highlighted in older patients and those who have a history of hypertension or existing cardiovascular disease. Official documents indicate that the use of the medicine necessitates careful consideration of the potential benefits and risks.

Q: Can Levid be taken if I am consuming alcohol (purely informational)?

A: Official labeling does not contain specific restrictions regarding alcohol; however, it is noted that alcohol consumption may worsen some of the potential nervous system side effects of Levofloxacin, such as dizziness and headache. This is a factual observation that is mentioned in official health information.

Q: Can Levid cause changes to skin or hair?

A: Official adverse reaction tables list skin-related reactions such as rash and itching, and an increased sensitivity to sunlight (photosensitivity). However, changes to hair are generally not listed as a reported adverse reaction in the regulatory documents.

Q: How quickly does Levid typically start to work?

A: Levofloxacin is designed to begin its activity against susceptible bacteria shortly after the first dose. The amount of time required for a patient to observe a clinical improvement in their symptoms depends on the specific type and severity of the infection being treated.

Q: Is Levid generally considered a long-term or short-term treatment?

A: According to official dosing guidelines, Levofloxacin is utilized for both short-term and longer-term treatment plans. The duration of therapy can range from as short as a few days up to approximately 60 days, depending entirely on the specific infection and clinical indication.

Q: Why do some people experience mild fatigue when first starting Levid?

A: Fatigue itself is not consistently listed as a primary common side effect across all major regulatory sources. However, official information does list hypoglycemia (low blood sugar) as a possible rare adverse reaction, and fatigue can be a symptom associated with low blood sugar levels.

Q: Does Levid need to be taken at a specific time of day?

A: Levofloxacin is typically prescribed to be taken once every 24 hours. The official instructions generally state that the specific time of day does not affect the drug's efficacy, but official guidance often suggests taking it at approximately the same time each day to support consistent levels in the body.

Q: Are there different forms or versions of Levid available (e.g., tablet, liquid)?

A: Official drug documents confirm that Levofloxacin is available as tablets for oral use. It is also available in different preparations, including a solution for intravenous (IV) infusion, an ophthalmic (eye) solution, and in some regions, an oral solution or liquid form.

Q: What is the duration of action for Levid?

A: Levofloxacin is designed to be taken once daily because its effects are sustained over a 24-hour period to effectively manage the infection. Official pharmacokinetic data indicates the drug has an average half-life in the body of approximately six to eight hours.

Q: Can Levid interact with certain vitamins or herbal products?

A: Yes, official labeling warns that Levofloxacin should not be taken within two hours of products containing multivalent cations, such as iron, calcium, or zinc. These elements are commonly found in antacids and many multivitamin or mineral supplements, and they can significantly reduce the absorption of Levofloxacin.

Q: How long does Levid stay in the system after the last intake?

A: Based on the drug's average half-life, it generally takes between 40 to 50 hours after the final dose for Levofloxacin to be almost entirely cleared from the body. Clearance is primarily handled by the kidneys, as described in official pharmacokinetic data.

Q: Are the effects of Levid different for men and women?

A: Regulatory pharmacokinetic studies have observed that the elimination of Levofloxacin may occur slower in women compared to men, which can lead to differences in overall drug exposure. However, official dosing is typically determined by kidney function and is not adjusted based on gender alone.

Q: How does the body typically process Levid?

A: Official pharmacokinetic descriptions state that Levofloxacin is primarily processed for excretion by the kidneys (renal elimination). The drug is excreted mostly as the unchanged compound and is not significantly metabolized by the liver.

Q: Do health authorities generally agree on the evidence for Levid?

A: Major global health authorities, including the U.S. FDA, the European EMA, and Health Canada, have granted approval based on the available body of clinical evidence for the treatment of susceptible bacterial infections.

Q: Is Levid a controlled substance?

A: Levofloxacin is classified as a medicine that requires a prescription for use. However, according to regulatory bodies in the United States and other major regions, it is not designated as a federally controlled substance.

Q: Are there reports of Levid causing sensitivity to the sun?

A: Yes, official warnings indicate that Levofloxacin is associated with an increased risk of photosensitivity, which is an increased sensitivity to sunlight or UV light. Official guidance indicates that it is important for patients to avoid excessive sun exposure and use sun protection.

Q: Does Levid cause changes in appetite or weight?

A: Some official regional regulatory sources have noted loss of appetite (anorexia) as a reported side effect of Levofloxacin. Changes in body weight are not typically specified or consistently noted in the main regulatory adverse reaction tables.

How should Levid be stored and disposed of?

How to Store and Dispose of Levid?

Levid (Levofloxacin) must be stored according to specific regulatory requirements to maintain its stability.


Storage Conditions

Requirement Official Instruction
Temperature Store tablets at Controlled Room Temperature, 20 C to 25 C.
Protection Protect from moisture, direct light, and excessive heat.
Handling Do not freeze the medicine in any form. Keep in a closed container.

Disposal and Safety

  • Child Safety: Store strictly out of the reach and sight of children.
  • Unused Product: The injection solution is for single-use only; discard any unused portion. Do not keep outdated medicine.
  • Disposal: Consult a healthcare professional for instruction on how to properly dispose of unused or expired Levid.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Levid found in:

A-Z Index: